STACEY JASKOLKA: Open Payments
NPI 1922437805 · UTICA, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,379 in 75 payments from 28 companies in 2025. Trend: 2023 $1,294 · 2024 $1,898 · 2025 $2,379
Food & beverage: $1,281Long term medical supply or device loan: $1,098
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 14 | $1,119 |
| Janssen Biotech, Inc. | 12 | $248 |
| Merck Sharp & Dohme LLC | 6 | $137 |
| AstraZeneca Pharmaceuticals LP | 4 | $83 |
| Daiichi Sankyo Inc. | 3 | $77 |
| Genentech USA, Inc. | 4 | $77 |
| Regeneron Healthcare Solutions, Inc. | 2 | $59 |
| Genmab U.S., Inc. | 2 | $48 |
| Eisai Inc. | 2 | $48 |
| ADC THERAPEUTICS AMERICA, INC. | 3 | $45 |
Products named: KISQALI, RYBREVANT, KEYTRUDA, Enhertu, LIBTAYO, Padcev, VENCLEXTA, Tivdak.
Industry payments across NY — which companies pay providers there.
